Ionis Pharmaceuticals, Inc. (IONS)
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript
Algert Global LLC Grows Position in Ionis Pharmaceuticals, Inc. $IONS
Algert Global LLC grew its position in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 562.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 252,281 shares of the company's stock after purchasing an additional 214,191 shares during the period. Algert Global LLC
Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ionis Pharmaceuticals: Digesting Recent Events
Ionis Pharmaceuticals recently raised Tryngolza's peak revenue estimate to over $2 billion after strong sHTG data, which has triggered a large stock rally since September 2025. IONS projects over $4 billion in peak annual product revenue, $2 billion in royalties, and $6 billion in milestones from its robust pipeline and partnerships. Management guides for cash-flow breakeven by 2028, with initial FY2026 guidance and a strong balance sheet supporting continued clinical advancement.
Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
IONS beats Q4 estimates on strong Tryngolza sales, but shares slip 5% as 2026 revenue outlook and slower uptake for new drugs weigh on sentiment.
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.66 per share a year ago.
Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
